The pharmaceutical dual ETA/ETB receptor antagonist or selective ETAR inhibitors reduces the mortality rate in the pulmonary arterial hypertension (PAH) patients [34]. The gene discussed is EDNRA; the disease is pulmonary arterial hypertension.